Pseudoprogression on PSMA PET imaging of a mCRPC patient under anti-PD1 treatment

Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1576-1577. doi: 10.1007/s00259-019-04328-1. Epub 2019 Apr 22.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Androstenes / administration & dosage
  • Anilides / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antigens, Surface / analysis*
  • Brachytherapy
  • Disease Progression
  • Gallium Radioisotopes
  • Gene Expression Regulation, Neoplastic
  • Glutamate Carboxypeptidase II / analysis*
  • Goserelin / administration & dosage
  • Humans
  • Ligands
  • Male
  • Nitriles / administration & dosage
  • Positron-Emission Tomography
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Prostatectomy
  • Prostatic Neoplasms, Castration-Resistant / diagnostic imaging*
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Salvage Therapy
  • Tosyl Compounds / administration & dosage

Substances

  • Androstenes
  • Anilides
  • Antibodies, Monoclonal, Humanized
  • Antigens, Surface
  • Gallium Radioisotopes
  • Ligands
  • Nitriles
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Tosyl Compounds
  • Goserelin
  • bicalutamide
  • pembrolizumab
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II
  • abiraterone